← All trials
NCT01982916
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2013
- Primary completion
- Sep 1, 2014
- Completion date
- Oct 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 330
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Ahn-Gook Pharmaceuticals Co.,LtdLead sponsor
- Inha UniversityOverall official - principal investigator
- Inha UniversityCollaborator
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversityCollaborator
- Konkuk UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Seoul National UniversityStudy chair
- Konkuk UniversityCollaborator
- Sungkyunkwan UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yonsei UniversityCollaborator
- Kyung Hee UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.